The DOI matches its Crossref record.
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis
Open accessAbstract
Gain-of-function D816V point mutation within the kinase domain of the transmembrane receptor KIT is found in the great majority of patients with systemic mastocytosis (SM) and is attractive therapeutic target. Twenty patients with SM were enrolled during 2003–2005 in phase II clinical trial with imatinib mesylate (400mg daily), a KIT inhibitor. Median time on therapy was 9 months (range, 0.5 – 44+). Only 1 patient, with D816V KIT mutation-negative FIP1L1-PDGFRα-negative SM-HES, achieved complete remission (now lasting for 44 months). Six other patients reported symptomatic improvement, including 2 with D816V KIT mutation-positive SM (one reported improvement in diarrhea and the other in fatigue). Other patients had no benefit. Imatinib was relatively well tolerated. Our study confirms that imatinib therapy does not result in appreciable clinical activity in patients with D816V mutation-positive SM, but may result in a significant benefit in occasional patient with D816V mutation-negative SM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
Valent, P., Akin, C., & Metcalfe, D. D. (2017) · Blood · doi:10.1182/blood-2016-09-731893 · Cited by 592
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
Lim, K.-H., Tefferi, A., Lasho, T. L., Finke, C., Patnaik, M., Butterfield, J. H., McClure, R. F., Li, C.-Y., & Pardanani, A. (2009) · Blood · doi:10.1182/blood-2009-02-205237 · Cited by 588
Imatinib: A Breakthrough of Targeted Therapy in Cancer
Iqbal, N., & Iqbal, N. (2014) · Chemotherapy Research and Practice · doi:10.1155/2014/357027 · Cited by 470
How I treat hypereosinophilic syndromes
Klion, A. D. (2015) · Blood · doi:10.1182/blood-2014-11-551614 · Cited by 296
Molderings, G. J., Brettner, S., Homann, J., & Afrin, L. B. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-10 · Cited by 149
Metadata
- Authors
- Vega-Ruiz, A., Cortes, J. E., Sever, M., Manshouri, T., Quintás-Cardama, A., Luthra, R., Kantarjian, H. M., & Verstovsek, S.
- Venue
- Leukemia Research
- Publisher
- Elsevier BV
- Published
- 2009-11
- Volume
- 33
- Issue
- 11
- Pages
- 1481-1484
- ISSN
- 0145-2126 (ISSN-L)
- OpenAlex
- W2126677578
- Cited by
- 163
- References
- 0
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. https://app.cochat.ai/papers/10.1016/j.leukres.2008.12.020
- The paper
- Vega-Ruiz, A., Cortes, J. E., Sever, M., Manshouri, T., Quintás-Cardama, A., Luthra, R., Kantarjian, H. M., & Verstovsek, S. (2009). Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leukemia Research. https://doi.org/10.1016/j.leukres.2008.12.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.